Abingdon Health Plc

LSE ABDX.L

Abingdon Health Plc EBIT Margin for the year ending June 30, 2024: -21.87%

Abingdon Health Plc EBIT Margin is -21.87% for the year ending June 30, 2024, a 74.60% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Abingdon Health Plc EBIT Margin for the year ending June 30, 2023 was -86.13%, a 88.70% change year over year.
Abingdon Health Plc EBIT Margin for the year ending June 30, 2022 was -762.47%, a -1,198.88% change year over year.
Abingdon Health Plc EBIT Margin for the year ending June 30, 2021 was -58.70%, a 10.54% change year over year.
Abingdon Health Plc EBIT Margin for the year ending June 30, 2020 was -65.62%, a -7.36% change year over year.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

LSE: ABDX.L

Abingdon Health Plc

CEO	Mr. Chris Henry Francis Yates
IPO Date	Dec. 15, 2020
Location	United Kingdom
Headquarters	York Biotech Campus
Employees	84
Sector	Health Care
Industries Pharmaceuticals Biotechnology Medical Instruments

Description

Abingdon Health Plc develops, manufactures, and distributes diagnostic devices worldwide. It offers AbC-19 Rapid Test, a COVID-19 IgG rapid antibody test; nucleic acid lateral flow immunoassays; Seralite, a rapid lateral flow test for the quantitative measurement of kappa and lambda immunoglobulin free light chains in serum; and AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader. The company also provides lateral flow development and manufacturing services. Additionally, it provides consultancy services to businesses in the healthcare technology sector. The company has a collaboration and co-marketing agreement with Abcam plc. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

Key trends

Past 5 years